Anthera Pharmaceuticals is discontinuing the development of Sollpura (lipromatase) as a treatment for cystic fibrosis-related digestive problems.
This follows the announcement of the latest data from the RESULT Phase 3 clinical trial (NCT03051490), which failed to demonstrate Sollpura’s effectiveness. The treatment was unable to significantly improve fat absorption, which was the primary goal of the trial.
The company is planning to evaluate all trial data. However, it will suspend Sollpura’s ongoing clinical studies, which include the extension study of the RESULT trial, the SIMPLICITY study (NCT02734810), and the EASY trial (NCT02823964).
